Early data from the UK and Japan show that the H3N2 subclade K was represented in 90% of flu samples.
High-dose vaccine was 40% more effective against hospitalization than the standard-dose version.
Our systematic review published this week shows that rigorous, transparent evidence synthesis can persist even when traditional advisory processes falter.
The large-scale project was conducted by the Center for Infectious Disease Research and Policy's Vaccine Integrity Project.
One study found fairly high rates of flu, mumps, and hepatitis A, and the other found that only 28% of adults have been vaccinated against tetanus and diphtheria.
Overall flu cases are 10.8% higher than last year across Australia.
Study shows vaccine effectiveness around 50% for both clinic visits and hospital stays for influenza during the 2025 Southern Hemisphere flu season.
The money will fund work on CD388, a non-vaccine preventive for both pandemic and seasonal flu.
The researchers note an increase in VE of 28 percentage points for a second dose in vaccine-naive children younger than 3 years but none when including children up to 8 years.
The Vaccine Integrity Project staff and advisors note the conspicuous and consequential absence of US health agency vaccine campaigns and annual vaccination reminders ahead of respiratory virus season.
